Hone Turns TRT into Platform

This is how Hone turns a hard won testosterone customer into a much larger recurring health account. TRT patients already do blood draws, meet clinicians, and adjust dosing over time, so once that workflow is in place, adding metformin, glutathione, B12, GLP-1s, or later women’s hormone care is not a new sale from scratch. It is another prescription and monitoring layer inside the same subscription engine.

• Hone’s base product naturally creates higher LTV than lighter telehealth categories. The business was built around a $129 per month consult subscription plus add ons like testosterone injections and anastrozole, with retention supported by ongoing lab work and dose changes, unlike ED and hair loss products that are easier to stop or substitute.
  1 sacra
• That matters because many D2C telehealth peers struggled to make cross sell work. Ro and Hims grew fast on low friction generic prescriptions, but high churn and rising CAC limited expansion, with ED still driving much of Ro’s revenue mix. Hone starts from a stickier clinical relationship, so each extra product lands on a more durable customer base.
  3 sacra 1 sacra
• The later product roadmap shows the model in action. By September 2025, Hone had expanded from men’s TRT into weight loss, longevity, and a women’s line, reaching an estimated $113.5M ARR. Function Health shows the adjacent lane, broad biomarker testing without treatment, while Hone bundles diagnostics with prescribing and follow up care, which gives it more ways to monetize each patient over time.
  2 sacra 4 sacra

The direction is toward a category specific telehealth platform built on recurring labs and prescribing, not a single product clinic. If Hone keeps layering new therapies onto the same monitoring and consult workflow, growth increasingly comes from raising revenue per member, which can make the business more resilient than telehealth models that depend on constantly buying new customers.